EMA401, An Orally Administered Highly Selective Angiotensin II Type 2 Receptor Antagonist, as a Novel Treatment for Postherpetic Neuralgia: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
Lancet 383:1637-1647, Rice, A.C.,et al, 2014
Use of Angiotension Receptor Blockers and Risk of Dementia in a Predominantly Male Population: Prospective Cohort Analysis
BMJ 340:141-147, 111, Li,N.-C.,et al, 2010
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Prophylactic Treatment of Migraine With an Angiotnesin II Receptor Blocker
JAMA 289:65-69, Tronvik,E.,et al, 2003
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Comparative Effects of Drug Interventions for the Acute Management of Migraine Episodes in Adults:Systematic Review and Network Meta-Analysis
BMJ 386:e080107, Karlsson,W.K.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013
Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012
New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate
Lancet 376:645-655, Edvinsson,L. &Linde,M., 2010
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Hypersexuality in Patients with Dementia: Possible Response to Cimetidine
Neurol 54:2024, Wiseman,S.V.,et al, 2000
Migraine in Pregnancy
Neurol 53:S26-S28, Aube,M., 1999
Drugs for Migraine
The Medical Letter 37:17-20, , 1995
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
Phenytoin and Ranitidine Interaction
Ann Int Med 120:892-893, Tse,C.S.T.&Iagmin,P., 1994
Treatment of Migraine
Lancet 339:1207-1209, Lance,J.W., 1992
Ranitidine Pharmacokinetics and Adverse Central Nervous System Reactions
Arch Int Med 152:2325-2329, Slugg,P.H.,et al, 1992
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991
Central Nervous System Reactions to Histamine-2 Receptor Blockers
Ann Int Med 114:1027-1034, Cantu,T.G.&Korck,J.S., 1991
Cimetidine Toxic Reactions Masquerading as Delirium Tremens
JAMA 245:1058-1059, Weddington,W.W.,et al, 1981
Cimetidine Interaction with Phenytoin
BMJ 282:1512, Hetzel,D.J.,et al, 1981
Delayed Clearance of Diazepam Due to Cimetidine
NEJM 302:1012-1014, Klotz,U.,et al, 1980
Motor Neuropathy Associated with Cimetidine
BMJ 281:974-975, Walls,T.J.,et al, 1980
Cimetidine & Mental Confusion
NEJM 298:284, 1978. (Letter), McMillen,M.A.,et al, 1978
Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice
Neurol 104:e213498, Zara,P.,et al, 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
A 60-Year-Old Man with Rapidly Progressive Left Hemibody Weakness and Vision Loss
Neurol 105: e213869, Rock,M.,et al, 2025
AAV9-Mediated Gene Therapy for Infantile-Onset Pompes Disease
NEJM 392:2438-2446, 2477, Ma,X.,et al, 2025
Clinicopathologic conference, Malignant Mixed Germ-Cell Tumor and Anti-NMDA Receptor Encephalitis
NEJM 303:488-496, Case 22-2025, 2025
A 72-Year-Old Man with Progressive Pan-Dysautonomia
Neurol 105:e213994, Zelikovich,A.S.,et al, 2025
A Woman with Subacute Progression of Distal Upper Extremity Weakness
Neurol 105:e214212, Zhao,A.J.,et al, 2025